Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal
This is a developing story.
Kimberly-Clark to buy embattled Tylenol maker Kenvue in a deal valued at more than $48 billion
Kenvue's stock, which had hit a record low in recent weeks, was headed for its best day ever while Kimberly-Clark's stock tumbled.
Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal
Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion.
Kimberly-Clark agrees to buy Kenvue in $48.7 billion deal, creating consumer staples giant
Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
Kimberly-Clark to Buy Kenvue in Deal That Values Tylenol Maker at $48.7 Billion
Kimberly-Clark will buy Kenvue for cash and stock.
Kimberly-Clark to acquire Kenvue in $48.7 billion deal
Kimberly-Clark said on Monday it will acquire Tylenol maker Kenvue in a deal valued at about $48.7 billion.
Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Embattled Tylenol Maker Kenvue Hires New Marketing Chief
The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.
Texas sued Tylenol maker Kenvue, alleging it deceived pregnant women about risks associated with autism
The suit alleges that the Tylenol maker engaged in deceptive marketing by advertising the product as safe to use while pregnant.
Buy 2 Ideal Dividend Kings Of 25 'Safer' In October's 56
This October's Dividend Kings list features 56 stocks, with Kenvue and United Bankshares meeting the ideal "fair price" yield criteria. Analysts project the top-ten Dividend Kings could deliver 19.2% to 41.5% net gains by October 2026, with KVUE offering the highest upside. Only two of the top-ten Kings, KVUE and UBSI, are considered "safer" with sufficient free cash flow to cover their dividends at current prices.
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.
RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?
Tylenol may be only the beginning.
